Disrupting DNA repair using PARP1/2 inhibitors (here forth referred to as PARP inhibitors) to induce cell death is a well-studied therapeutic approach, particularly for breast cancer [11, 12]. The gene discussed is PARP1; the disease is breast carcinoma.